HealthQuill Acquisition
AbbVie Inc., will buy Cerevel Therapeutics, developing drugs for neuroscience diseases, for $8.7 billion in a bid to boost the North Chicago, Illinois-based company’s presence in the psychiatric and neurological disorder segment.
Drugs Health Pharma

AbbVie to acquire Cerevel for $8.7b to bolster neurological treatments

HQ Team December 7, 2023: AbbVie Inc., will buy Cerevel Therapeutics, developing drugs for neuroscience diseases, for $8.7 billion in a bid to.

Read More
AbbVie Inc., operating in therapeutic areas such as immunology, oncology, neuroscience, and eye care, announced a pact to acquire ImmunoGen, Inc., for $10.1 billion. Image Credit: AbbVie
Drugs Health Pharma

AbbVie to buy Immunogen for $10.1b to expand solid tumour market

HQ Team November 30, 2023: AbbVie Inc., operating in therapeutic areas such as immunology, oncology, neuroscience, and eye care, announced a pact to.

Read More
Shareholders of Abcam Plc., a UK-based manufacturer and supplier of antibodies and reagents used for medical research, have approved a plan from US’s Danaher Corp to acquire the company for $5.7 billion.
Drugs Health Pharma

Abcam shareholders approve Danaher Corp acquisition for $5.7 billion

HQ Team November 7, 2023: Shareholders of Abcam Plc., a UK-based manufacturer and supplier of antibodies and reagents used for medical research, have.

Read More
Bristol Myers Squibb, one of the world’s largest pharmaceutical companies, will acquire Mirati Therapeutics for $5.8 billion through a combination of cash and debt to broaden its cancer portfolio.
Drugs Health Pharma

Bristol Myers acquires Mirati Therapeutics for $5.8 billion

HQ Team October 9, 2023: Bristol Myers Squibb, one of the world’s largest pharmaceutical companies, will acquire Mirati Therapeutics for $5.8 billion through.

Read More
Amgen Inc., a US biotechnology company, completed the acquisition of Horizon Therapeutics Plc for $27.8 billion, gaining access to the Dublin-based firm’s two drugs that treat rare inflammatory diseases.
Drugs Health Pharma

Amgen completes $27.8b acquisition of Horizon Therapeutics

Amgen Inc., a US biotechnology company, completed the acquisition of Horizon Therapeutics Plc for $27.8 billion, gaining access to the Dublin-based firm’s two.

Read More
Cordis, a US-based medical device maker, has acquired Switzerland’s MedAlliance for up to $1.1 billion to expand its product portfolio.
Health Medical Pharma

Cordis acquires medical device maker MedAlliance for $1.1 billion

HQ Team October 2, 2023: Cordis, a US-based medical device maker, has acquired Switzerland’s MedAlliance for up to $1.1 billion to expand its.

Read More
Biocon Ltd., an Indian biopharmaceutical company, has acquired Eywa Pharma Inc., an oral solid dosage manufacturing facility in the US for $7.7  million.
Drugs Health Pharma

Biocon buys Eywa Pharma’s US facility for $7.7 million

HQ Team September 6, 2023: Biocon Ltd., an Indian biopharmaceutical company, has acquired Eywa Pharma Inc., an oral solid dosage manufacturing facility in.

Read More
Eli Lily sold its sugar-controlling drug to Amphastar Pharmaceuticals for $1.07 billion.
Drugs Health Pharma

Eli Lilly to sell diabetic nasal drug to Amphastar for $1.07 billion 

Eli Lily sold its sugar-controlling drug to Amphastar Pharmaceuticals for $1.07 billion.

Read More
US-based Merck will buy Prometheus Biosciences for about 10.8 billion to shore up its immunology portfolio to shield itself from eventual revenue loss as patents on its cancer immunotherapy Keytruda expires by the end of the decade.
Drugs Pharma

Merck to acquire Prometheus for $10.8 billion to step up immunology presence

HQ Team April 17, 2023: US-based Merck will buy Prometheus Biosciences for about 10.8 billion to shore up its immunology portfolio to shield itself from.

Read More
Dr. Reddy’s Laboratories, an Indian maker of generics and active pharmaceutical ingredients, has completed the acquisition of Mayne Pharma’s U.S. generic prescription portfolio.
Drugs Health Medical Pharma

Dr. Reddy’s completes Mayne Pharma’s U.S. portfolio buyout

H.Q. Team April 7, 2023: Dr. Reddy’s Laboratories, an Indian maker of generics and active pharmaceutical ingredients, has completed the acquisition of Mayne.

Read More